State Street Corp Purchases Shares of 81,059 Alumis Inc. (NASDAQ:ALMS)

State Street Corp acquired a new stake in Alumis Inc. (NASDAQ:ALMS - Free Report) in the third quarter, according to its most recent filing with the SEC. The fund acquired 81,059 shares of the company's stock, valued at approximately $866,000. State Street Corp owned approximately 0.17% of Alumis at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALMS. BNP Paribas Financial Markets purchased a new position in shares of Alumis in the third quarter valued at $27,000. MetLife Investment Management LLC bought a new position in Alumis in the 3rd quarter worth about $89,000. Maven Securities LTD purchased a new position in Alumis during the 2nd quarter valued at about $332,000. Towerview LLC increased its position in shares of Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after buying an additional 70,000 shares during the period. Finally, Stifel Financial Corp purchased a new stake in shares of Alumis in the third quarter worth about $931,000.

Wall Street Analysts Forecast Growth

ALMS has been the topic of a number of analyst reports. Robert W. Baird started coverage on shares of Alumis in a report on Thursday, October 31st. They set an "outperform" rating and a $25.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $26.00 price target on shares of Alumis in a report on Friday, December 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Finally, Baird R W upgraded Alumis to a "strong-buy" rating in a research note on Thursday, October 31st. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Alumis has a consensus rating of "Buy" and an average target price of $26.83.

Alumis Stock Up 2.8 %

ALMS stock traded up $0.23 during mid-day trading on Friday, hitting $8.45. 83,508 shares of the stock were exchanged, compared to its average volume of 75,754. The firm's fifty day simple moving average is $9.48. Alumis Inc. has a 12 month low of $7.46 and a 12 month high of $13.53.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.